One of the drugs taken by Donald Trump that he has touted as a potential “cure” for coronavirus was developed using human cells originally obtained from an elective abortion, a practice repeatedly denounced by the president and many of his supporters.
The drug is a monoclonal antibody cocktail developed by Regeneron. The president received an 8-gram infusion under a “compassionate use” exemption when he was hospitalized over the weekend after testing positive for Covid-19. There is no cure for Covid-19, and the drug is not approved.
The cells used to develop the drug are known as HEK-293T cells, a line of cells used in laboratories. The cells were originally derived from an embryonic kidney after an elective abortion performed in the Netherlands in the 1970s.
Trump has consistently sought to restrict abortion access, including most recently, when he nominated the conservative Catholic Judge Amy Coney Barrett to the supreme court last month. The anti-abortion movement is one of Trump’s most enthusiastic bases of support.
The 2020 Republican party platform explicitly opposes embryonic stem cell research, and calls for a ban on federal funding for embryonic stem cell research, because like HEK cells they are derived from an embryo.
Trump has already limited research using embryonic stem cells for ideological reasons. In 2019, his administration paused funding for government scientists to work on studies involving embryonic stem cells, affecting about $31m in research, according to Science Magazine.
“We stopped the federal funding of fetal tissue research, which everybody felt was so important …” the president told supporters in January 2020. “We’re standing up to the pro-abortion lobby like never before.”
The HEK-293T line of cells has been “immortalized”, meaning they divide freely in the lab. Regeneron said the company does not consider the cells “tissue”.
READ ALSO: PMB, THIS SON OF A TEACHER SAYS THANK YOU
“It’s how you want to parse it,” a Regeneron spokeswoman, Alexandra Bowie, told the MIT Technology Review. “But the 293T cell lines available today are not considered fetal tissue, and we did not otherwise use fetal tissue.”
Development of the Regeneron antibody cocktail is supported by a $450m grant from the Biomedical Advanced Research and Development Authority (Barda).
Regeneron has worked with the US government to develop monoclonal antibody therapies for years. In 2018, researchers from Regeneron and the US government used the same line of cells in development of a therapy for the Ebola virus, according to a study published in the Journal of Infectious Diseases.
“Research using such stem cells allows Regeneron to model complex diseases, test new drug candidates and can help unlock new scientific insights that ultimately could lead to the discovery of new treatments for people with serious diseases,” Regeneron said in an April 2020 statement about stem cells in general.
Regeneron’s drug is not available to the public and has been tested on only 275 people to date. Therapies in the same class as Regeneron’s antibody cocktail cost on average more than $96,000 a course.
The UK Guardian
